Gonadotropin-releasing hormone agonist triggering is effective, even at a low dose, for final oocyte maturation in ART cycles: Case series.

OBJECTIVE To investigate the efficacy of low-dose gonadotropin-releasing hormone (GnRH) agonist for final oocyte maturation in females undergoing assisted reproductive treatment (ART) cycles. MATERIAL AND METHODS Nine females undergoing ovarian stimulation in a GnRH antagonist protocol who received triptorelin 0.1 mg to trigger final oocyte maturation were included. Treatment outcomes of these patients were compared with those of controls, matched for age and oocyte number (n=14), who received 0.2 mg triptorelin at the same time. The luteal phase was supported with vaginal micronized progesterone and oral estradiol hemihydrate 2 mg twice daily. RESULTS The mean (±) numbers of retrieved, metaphase II, and fertilized oocytes were 15.66±7.82, 14±7.28, and 10.11±5.86, respectively. The implantation and clinical pregnancy rates were 46.1% and 71.4%, respectively. Of the pregnancies, 2 were live births, 1 was a preterm birth (twins), 2 are on-going, and 2 ended as miscarriages. No case of OHSS was encountered. On comparison of the results of these patients (fresh cycles; n=7) with those of matched controls, there were no significant differences in terms of retrieved mature oocytes, implantation rates, or clinical pregnancy rates (p>0.05). CONCLUSION These findings suggest that low-dose GnRH agonist triggering has similar efficacy as standard doses in terms of retrieved mature oocytes and clinical pregnancy rates in in vitro fertilization cycles.

[1]  S. Iliodromiti,et al.  Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study. , 2013, Human reproduction.

[2]  P. Humaidan,et al.  GnRH agonist triggering: recent developments. , 2013, Reproductive biomedicine online.

[3]  F. Martínez,et al.  Triggering ovulation with 250 μg or 500 μg of r-hCG in oocyte donors treated with antagonist protocol has no effect on the number of mature oocytes retrieved: a randomized clinical trial , 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[4]  C. Benadiva,et al.  Agonist trigger: what is the best approach? Agonist trigger with aggressive luteal support. , 2012, Fertility and sterility.

[5]  D. Meldrum.  Preventing severe OHSS has many different facets. , 2012, Fertility and Sterility.

[6]  M. Aboulghar.  Agonist and antagonist coast. , 2012, Fertility and sterility.

[7]  P. Devroey,et al.  The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. , 2012, Reproductive biomedicine online.

[8]  P. Humaidan,et al.  Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS , 2012, Journal of Assisted Reproduction and Genetics.

[9]  J. Segars,et al.  The prevalence of genuine empty follicle syndrome. , 2011, Fertility and sterility.

[10]  F. Guimiot,et al.  GnRH receptor mutations in isolated gonadotropic deficiency , 2011, Molecular and Cellular Endocrinology.

[11]  O. Coll,et al.  Exploring two different doses of GnRH agonist for the induction of final oocyte maturation in GnRH antagonist-treated oocyte donor cycles: a retrospective comparison , 2011 .

[12]  S. Daneshmand,et al.  Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin. , 2011, Fertility and sterility.

[13]  C. Racowsky,et al.  Crinone vaginal gel is equally effective and better tolerated than intramuscular progesterone for luteal phase support in in vitro fertilization-embryo transfer cycles: a prospective randomized study. , 2010, Fertility and sterility.

[14]  P. Humaidan,et al.  LH (as HCG) and FSH surges for final oocyte maturation: sometimes it takes two to tango? , 2010, Reproductive biomedicine online.

[15]  B. Tarlatzis,et al.  GnRHa to trigger final oocyte maturation: a time to reconsider. , 2010, Human reproduction.

[16]  E. Kolibianakis,et al.  GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. , 2006, Human reproduction update.

[17]  P. Parneix,et al.  Comparaison de différents protocoles de déclenchement de l’ovulation, par agonistes du GnRH et gonadotrophine chorionique Triggering of ovulation using different regimens of gonadotropin-releasing hormone agonist or human chorionic gonadotropin. , 2001 .

[18]  C. Quintans,et al.  Empty follicle syndrome due to human errors: its occurrence in an in-vitro fertilization programme. , 1998, Human reproduction.

[19]  E. Shalev,et al.  Gonadotrophin-releasing hormone agonist compared with human chorionic gonadotrophin for ovulation induction after clomiphene citrate treatment. , 1995, Human reproduction.

[20]  E. Altieri,et al.  The empty follicle syndrome: a pharmaceutical industry syndrome. , 1995, Human reproduction.

[21]  Z. Shoham,et al.  The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering. , 1995, Fertility and sterility.

[22]  E. Shalev,et al.  Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome. , 1994, Human reproduction.

[23]  L. Kahana,et al.  Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. , 1991, Fertility and sterility.

[24]  F. Okonofua,et al.  The effect of the dose of human chorionic gonadotropin and the type of gonadotropin stimulation on oocyte recovery rates in an in vitro fertilization program. , 1987, Fertility and sterility.

[25]  R. Feinn,et al.  Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger. , 2013, Human reproduction.

[26]  M. van Wely,et al.  GnRHa to trigger final oocyte maturation: a time to reconsider. , 2010, Human reproduction.

[27]  L. Nardo,et al.  Symposium: Update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence? , 2009, Reproductive biomedicine online.

[28]  J. Nulsen,et al.  The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. , 2008, Fertility and sterility.

[29]  J. Emperaire,et al.  Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. , 2004, Reproductive biomedicine online.

[30]  P. Parneix,et al.  [Comparison of different protocols of ovulation induction, by GnRH agonists and chorionic gonadotropin]. , 2001, Gynécologie Obstétrique & Fertilité.